<DOC>
	<DOC>NCT00594646</DOC>
	<brief_summary>This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.</brief_summary>
	<brief_title>HIV Non Occupational Post-Exposure Prophylaxis (PEP)</brief_title>
	<detailed_description>This study will evaluate a three drug regimen in the form of two pills which will be taken for 28 days for the prevention of HIV infection. Two drugs are combined in an FDA-approved pill called TRUVADA, containing the HIV medications, tenofovir disoproxil fumarate 300mg and emtricitabine 200mg, taken as one pill once a day. The third drug is a new formulation, raltegravir 400mg pill taken twice a day.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV uninfected on the basis of a negative HIV Rapid Test, EIA or Western blot, and a negative HIV1 RNA assay Possible nonoccupational exposure to HIV1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure. Able to understand the study procedures and willing to sign informed consent Any active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures. Pregnancy. Chronic hepatitis B infection, diagnosed by either positive serum HBsAg or positive serum HBV DNA; or prior lamivudine therapy for hepatitis B. Creatinine clearance less than 50 mL/min as calculated by CockcroftGault formula. Unwillingness to participate in study procedures, including Mental Health referral and intervention. Known intolerance or allergy to tenofovir DF, emtricitabine or raltegravir. Use of prohibited concomitant medication: dilantin, phenobarbital and rifampin which cannot be used with raltegravir.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV Prevention</keyword>
	<keyword>Non-occupational post-exposure prophylaxis</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>